drugset / Trial / NCT02764892

A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease

NCT02764892

Phase 1 Completed 6 enrolled Vernalis (R&D) Ltd
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of the study is to identify the best dose of V81444 to use in future trials in patients with Parkinson's disease. The study will also explore the effects of V81444 on brain activity and blood flow with tests of mental ability ("cognitive function tests"). It will also check how safe V81444 is and how well it is tolerated after dosing.

Timeline

Start
2012-08
Primary completion
2012-11
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciforadenant Small molecule 50 mg Oral
Subject Ciforadenant Small molecule 100 mg Oral
Subject Ciforadenant Small molecule 250 mg Oral

Indications